NFE2L2 and urinary bladder carcinoma: In this study, we investigated the underlying molecular mechanism by which the NEDD4-mediated KLF8/miR-132/NRF2 axis fine-tunes the malignant phenotypes of bladder cancer cells using in vitro and in vivo assays (Fig. 8), providing a promising therapeutic target for treating patients with bladder cancer.